Legend Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Legend Biotech Corporation (LEGN): Among Hedge Funds' Top Biotech Stock Picks
Peering Into Legend Biotech's Recent Short Interest
Legend Biotech Down Over 10%, on Pace for Largest Percent Decrease Since July 2022 -- Data Talk
Express News | Fidelity Greater China Fund reduced its holdings of ICBC, Kweichow Moutai, and TSMC, and cleared its positions in Luxshare Precision, while increasing its holdings of PetroChina.
Matthews Emerging Markets Small Companies Fund Boosts Stake in Legend Biotech Corp
HK stocks surge | Genscript Bio (01548) rose nearly 4%, legend biotech's 'Siddarioncel' has been approved for domestic listing.
Genscript Bio (01548) rose nearly 4%, as of press time, up 3.79%, at HK$12.04, with a turnover of HK$39.6598 million.
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Legend Biotech Analyst Ratings
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright analyst Mitchell Kapoor maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $73.According to TipRanks data, the analyst has a success rate of 40.1%
Legend Biotech: CAR-T therapy Cardiwell has been approved for marketing by the National Medical Products Administration.
Legend Biotech announced on August 27 that its CAR-T therapy, Kawa Di, has been approved by the National Medical Products Administration (NMPA) for the treatment of relapsed or refractory multiple myeloma (R/R MM) in adult patients who have previously received at least third-line therapy (including the use of a proteasome inhibitor and an immunomodulatory agent).
"Million-dollar anticancer drugs" debut! Legend Biotech enters the domestic market, pricing attracts attention. Can CAR-T therapy break the deadlock in the four-country negotiations? | Industry Observation
①The sixth domestic CAR-T therapy, legend biotech's Xidajiouansai injection (trade name: Kawedi), was approved for marketing in the country on the 27th; ②In addition to exploring more indications, multiple CAR-T therapies including Akerunsai injection will continue to participate in national negotiations this year in the hope of entering medical insurance; ③Industry experts believe that the application prospects of CAR-T therapy are broad, and the key to market promotion lies in the price.
Legend Biotech Says China's National Medical Products Administration Approves Cell Therapy Product to Treat Multiple Myeloma
Express News | Legend Biotech: Received Approval From China National Medical Products Administration for Cell Therapy Product, Ciltacabtagene Autoleucel (Cilta-Cel)
Express News | Legend Biotech's pharmaceutical product Cawodi (sildenafil citrate injection) has been approved for market in China.
Legend Biotech's New Cancer Drug Wins Approval
Express News | Legend Biotech: China's Nmpa Approves Ciltacabtagene Autoleucel for Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
Genscript Bio (01548.HK): The new drug application for Sida Jiaolun Sai (cilta-cel) submitted by Legend Biotech has been approved.
On August 27, Genscript Bio (01548.HK) announced that on August 27, 2024, the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for cilta-cel submitted by its non-wholly owned subsidiary, Legend Biotech Co., Ltd. The product is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who meet the specified criteria.
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference